| Bioactivity | ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer. |
| Target | polycomb repressive complex 2; PRC2 |
| In Vivo | ORIC-944 (30，100，200 mg/kg； 口服； 每天一次持续 50 天）在所有剂量水平下均可诱导肿瘤显著消退[3]。ORIC-944 (30 mg/kg； 口服； 每天一次持续 30 天) 对 enzalutamide 具有很强的单药活性在前列腺癌异种移植模型[3]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 2369769-29-7 |
| Formula | C26H25FN6O |
| Molar Mass | 456.51 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Daemen A, et al. ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models[J]. Cancer Research, 2024, 84(6_Supplement): 6586-6586. [2]. ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones [3]. Daemen A, et al. ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates robust in vivo activity in prostate cancer models[C]//Cancer Research. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2021, 81(13). |